Open-Label, Randomized Phase 1b Study of the Safety and Immunogenicity of Investigational Seasonal Influenza DNA Vaccine Followed by TIV Administered Intradermally (ID) or Intramuscularly (IM) in Healthy Adults 18-70 Years
Latest Information Update: 26 Aug 2022
At a glance
- Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary) ; VRC-FLUDNA063-00-VP (Primary) ; MF 59
- Indications Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Sep 2012 New trial record